Zeneca/Voluntary Hospitals of America
Executive Summary
Sign five-year deal for VHA to market to its hospitals the general anesthetic for ICU use Dipriven (propofol) and the cephalosporin Cefoten (cefotetan) under its private label VHA+PLUS. Zeneca says the deal will enhance usage of Cefotan as the only second-generation cephalosporin VHA+PLUS drug and will keep sales levels up for Diprivan until 1999. Diprivan's patent expires in 1996. VHA has 1,103 hospitals in its network, representing "nearly 18% of all community hospitals in the country"
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth